Renalytix Share Discussion Threads

[dontshoutatonce] 06/4/2021 19:09

Agreed flying. The news is there for all to see and it looks as though the FDA approval is a mere formality, so why isn't it leaping? The whole great story is before us. A company this important should have a share price considerably higher, and given time, it must come. Was Easter that good for some people that they haven't woken up yet?

[flyinggogo] 06/4/2021 16:40

Considering the news in your links, the price action is maybe a little disappointing today. I guess we will fly under the radar until FDA approval

[mr roper] 05/4/2021 14:18

hxxps://investors.renalytixai.com/news-releases/news-release-details/multi-center-study-finds-kidneyintelx-72-more-effective-current

Multi-Center Study Finds KidneyIntelX 72% More Effective Than Current Standard of Care In Identifying Early-Stage Patients at High Risk for Kidney Disease Progression and Failure

April 5, 2021
Download PDF
Clinical findings published in the April issue of Diabetologia, the official journal of the European Association for the Study of Diabetes

NEW YORK, April 05, 2021 (GLOBE NEWSWIRE) -- RenalytixAI plc (LSE: RENX) (NASDAQ: RNLX), announced today that KidneyIntelX™ more accurately predicted progressive kidney function decline and kidney failure in a multi-center, diverse cohort of 1,146 type 2 diabetes patients with early-stage (stages 1, 2, and 3) kidney disease versus the current standard of care. The results of the study, which is the second peer-reviewed clinical validation study on KidneyIntelX, have been published in Diabetologia, the official journal of the European Association for the Study of Diabetes (EASD).

Strong performance of the KidneyIntelX platform is attributed in part to its proprietary, blood-based biomarker technologies, exclusively licensed from the Joslin Diabetes Center and the Mount Sinai Health System.

Notably, KidneyIntelX was observed to be highly effective at both ends of the risk spectrum. In the study, KidneyIntelX more accurately identified and segmented patients into three risk categories (low, intermediate and high) when compared to clinical models, including the current standard of care, the KDIGO risk stratification algorithm. When guideline-recommended urine albumin to creatinine ratio testing was performed, the positive predictive value (PPV) for progressive decline in kidney function was 69% for those scored as high-risk by KidneyIntelX versus the 40% identified as highest-risk by KDIGO categorization. This is a 72% improvement compared to standard of care. In addition, only 7% of those scored as low-risk by KidneyIntelX experienced progression (i.e., negative predictive value of 93%).

“Diabetes is one of the leading causes of kidney failure in the United States. Appropriate treatment for kidney disease is a significant challenge in type 2 diabetes patients,” said Dr. Marina Basina, Clinical Professor, Medicine - Endocrinology, Gerontology, & Metabolism, Stanford Medicine and Medical Director of Inpatient Diabetes, Stanford Health Care. “Data from the KidneyIntelX risk assessment platform could significantly improve the care path for diabetes patients and delay the severe consequences of diabetic kidney disease. Identifying the risk for kidney disease complications in diabetic patients in the earlier stages of the disease is essential to improving kidney health and reducing health care costs.”

Accurate segmentation of patient groups based on risk will yield benefits from targeted clinical care plans. High-risk patients identified earlier in the disease cycle can be prioritized to receive precision medicine and optimized care management to slow or arrest progressive kidney disease, while low-risk patients can avoid unnecessary treatments, follow-up visits and anxiety. KidneyIntelX has the potential to uniquely inform health care providers, insurance payors and population health managers about the expected rate of progression and risk of failure in early-stage kidney disease patients. KidneyIntelX is expected to support optimization of care delivery, improve patient outcomes and reduce the $120 billion annual cost of kidney disease to the United States Medicare system.1

“Given these additional clinical study findings, we are confident that KidneyIntelX will be adopted as part of the standard of care in assessing the risk of progressive kidney decline in individuals with early-stage diabetic kidney disease,” said Michael J. Donovan, MD, Ph.D., Chief Medical Officer, RenalytixAI. “These results published in Diabetologia further validate our rigorous scientific and clinical approach, which is focused on early detection and aggressive clinical intervention for those found to be at the highest risk.”

The Diabetologia article entitled, “Derivation and validation of a machine learning risk score using biomarker and electronic patient data to predict progression of diabetic kidney disease,” is available at hxxps://link.springer.com/article/10.1007/s00125-021-05444

[mr roper] 05/4/2021 13:30

The Easter Bunny has brought some pretty good news Stateside.

[tradertrev] 30/3/2021 19:29

Bond yields

[spittingbarrel] 30/3/2021 18:07

Any news we should know about?

[mr roper] 24/3/2021 14:29

Should see revenue generation starting in the current quarter.
Fda back to normal service from April 15, so I’d be thinking approval could come anytime between May-end Aug.
Also expecting and other couple of partnerships to be announced in H1
Trial readout in September.
More partnerships in H2.

There is a lot going on.....expecting interest to pick up again shortly as vol has been fading for the last week or so

[dontshoutatonce] 24/3/2021 11:15

Flyinggogo. You're not late at all. Welcome. The others aren't even late and the Nasdaq's in one of it's quiet, low moods so nothing much is happening over there but RENX (RLNX) is holding up well amongst the others. Insurers and Medicare are involved as it holds a lot more hope for those unfortunate kidney sufferers who hitherto have found out too late about their poor health. That is many millions of people stateside and then the European (it is an English company after all,) and later other regions will have it because it is life-saving and everyone including governments, will save a lot of money to boot. I see this as a multi-bagger. Though it is relatively (and promisingly) small at $745m for its importance and with few employees, it is establishing itself in perhaps the most famous hospital group in the USA where the kidney machines are already being installed. There is no reason to think the machines won't become standard in many hospitals to combat kidney disease. 37 million people in the USA and approximately 850 million sufferers worldwide. Its present concentration is in N. America. I should think you know all this but it seems to be largely overlooked at the moment. I look forward to Nasdaq's turnaround and our next step up. Good luck.

[mr roper] 22/3/2021 08:49

Thanks for posting. Good watch that. Randy Barrons stat at the end on the cancer co with 23bn dollar mkt cap and no revenue is interesting indeed. Do the math...as he’d say

[flyinggogo] 22/3/2021 08:15

Spread had reduced to 20p this morning, in for 200 shares at 1067p. A little late to the party but hopefully earlier than the crowd...Theres an interesting nasdaq #tradetalks on youtube with the CEO James Mccullough, might be useful for other holders/prospective buyers.Youtube.com/watch?v=OskEo-ItNmY

[wan] 22/3/2021 07:39

Food for thought -

Renalytix CEO was previously the chief executive officer of Exosome Diagnostics, a venture backed personalised medicine company developing non-invasive liquid biopsy diagnostics in cancer. Exosome Diagnostics was acquired by Bio-Techne Corporation (NASDAQ: TECH).

What caught my attention some time ago was that Exosome (now a subsidiary of Bio-Techne), who are particularly focused on a prostate cancer test, was developing a novel urine test to diagnose human kidney transplant rejection. Such a test may be of relevance and interest to Renalytix/Verici.

These recent findings are thus very encouraging -

A study by investigators from Brigham and Women's Hospital and Exosome Diagnostics proposes a new, noninvasive way to test for transplant rejection using exosomes from urine samples. Their findings are published in the Journal of the American Society of Nephrology -

March 2021
Discovery and Validation of a Urinary Exosome mRNA Signature for the Diagnosis of Human Kidney Transplant Rejection

Significance Statement
The traditional biomarkers currently used to monitor a kidney allograft for rejection are late markers of injury and they lack sensitivity and specificity. Allograft biopsies on the other hand, are invasive and costly. The authors describe the discovery and validation of two urinary exosomal mRNA multigene signatures for the diagnosis of acute T cell–mediated and antibody-mediated rejection and chronic, active antibody-mediated rejection in recipients of kidney transplant. Using a clinically validated platform for exosome isolation and analysis, they demonstrated the high stability of urinary exosomes and the reliability of this approach in monitoring patients for allograft rejection. One gene signature for all-cause rejection and another for discriminating T cell–mediated rejection from antibody-mediated rejection showed high predictive performances and offer clinicians the possibility of new tools for monitoring emergence of rejection in kidney allografts.

Conclusions Our findings show that mRNA signatures derived from urinary exosomes represent a powerful and noninvasive tool to screen for kidney allograft rejection. This finding has the potential to assist clinicians in therapeutic decision making.

[serratia] 20/3/2021 19:16

If you go to the LSE site - London stock exchange you can see the trades and prices paid. Looks like a 30p spread on friday.

[busterdog2] 20/3/2021 17:12

Is the spread really as big as it appears? Try a dummy buy.

[flyinggogo] 20/3/2021 13:28

Newbie here looking to make a purchase soon. Can anyone tell me if the spread was much tighter under 1000p or has it been 50p spread for a while? Thanks in advance

[wan] 20/3/2021 07:09

Renalytix goal is to lower healthcare costs and improve patient quality of life by transforming the paradigm for kidney disease risk assessment and clinical management through their KidneyIntelX platform. Renalytix are engaging with multiple healthcare institutions and national payors regarding additional partnership opportunities.

A worthwhile read -

March 18, 2021
Kidney Care Choices models address urgent need to improve detection, management of CKD

According to the National Kidney Foundation, 1:7 people in the United States – about 15% of the adult population – have some form of chronic kidney disease.

Those numbers – accounting for close to 37 million residents – worry Kavita Patel, MD, a primary care physician who works 2 to 3 days a week at Mary’s Center, a federally qualified health clinic in Washington, D.C., where she sees patients who have been left out of mainstream health care in the United States.

New approach
As a non-resident fellow in the department of economic studies at the Brookings Institution, Patel helps health care systems change their clinical environments to become more accountable for the care they offer to patients who check in at places like Mary’s Center.

“You won’t meet a lot of people on boards of companies who also work in a public community health center,” Patel said. “This is relevant to my life. Kidney disease impacts a substantial percentage of U.S. adults, and the percentage continues to grow.”

CMS wants to target these patients with its Kidney Care Choices (KCC) demonstration, scheduled to start in April. The agency has been reviewing applications for the voluntary models, which have four variants (see sidebar).

Early intervention
Dialysis organizations DaVita Inc. and Fresenius Medical Care North America, which manage almost 70% of the U.S. dialysis population, have formed physician-based organizations that will direct some of the KCC models. Leslie Wong, MD, and Terry Ketchersid, MD, lead physician-directed organizations at DaVita and FMCNA, respectively, and see Kidney Care First as an opportunity to even the kidney disease playing field.

Full article -

DaVita Inc, gets a lot coverage/comment in the above article, recall that Renalytix has partnered with DaVita -

NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Kidney care innovators Renalytix AI (NASDAQ:RNLX, LSE:RENX) and DaVita (NYSE: DVA) are partnering on a program aimed at slowing disease progression and improving health outcomes for the nation’s estimated 37 million adults with chronic kidney disease (CKD). The program is expected to improve patient outcomes and provide meaningful cost reductions for health care providers and payors by enabling earlier intervention for patients with early-stage kidney disease (stages 1, 2 and 3) through actionable risk assessments and end-to-end care management.

The collaboration is expected to launch in three major markets this year. As the program expands, DaVita and RenalytixAI intend to pursue risk-sharing arrangements with health care providers and payors to drive kidney disease patient care innovation, cost efficiencies and improve quality of life.

“Almost 50% of people whose kidneys fail find out after it is too late, and we are on a mission to change that,” said Javier Rodriguez, Chief Executive Officer for DaVita. “Our partnership with RenalytixAI could allow us to help slow disease progression for the millions of people living with kidney disease.”

Full release -

[mr roper] 19/3/2021 16:39

Just a bounce back from yesterday.

[homebrewruss] 19/3/2021 16:05

Share price looking perky suddenly, especially stateside

[fardistanthills] 16/3/2021 09:30

Yes, thanks wan - appreciated.

[mr roper] 16/3/2021 08:37

That’s the one. Thank you very much

[wan] 16/3/2021 08:28

I was tidying up and took it out, but it's back in the Header.

[mr roper] 16/3/2021 08:10

Hi wan, any chance we could get the daily chart back in the header somewhere?

Thanks, Mr R

[fardistanthills] 15/3/2021 08:17

Wan and mginvestor! My apologies - earlier post deleted.

[mr roper] 14/3/2021 18:53

Hpcg, the bioutah podcast would suggest we are at the ground floor of a hundred story building. I think the story isn’t even really getting started yet.

[hpcg] 14/3/2021 16:25

Mr Roper, dp - being essentially a US company I concur that those running and invested in it are interested in making a lot of money over a long time, not a small amount over a short period. It is one of the reasons the US has big modern companies and the UK doesn't.